Gad Rennert1, Mila Pinchev, Hedy S Rennert, Stephen B Gruber. 1. Department of Community Medicine and Epidemiology, Carmel Medical Center, Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, and Clalit Health Services National Cancer Control Center, Haifa, Israel. rennert@tx.technion.ac.il
Abstract
PURPOSE: Bisphosphonates are commonly used for the treatment of osteoporosis and bone metastases caused by breast cancer and were recently reported to be associated with a reduced risk of breast cancer, possibly acting through the mevalonate pathway, but their association with risk of other cancers is unknown. PATIENTS AND METHODS: The Molecular Epidemiology of Colorectal Cancer study is a population-based, case-control study in northern Israel of patients with colorectal cancer and age-, sex-, clinic-, and ethnic group-matched controls. Long-term use of bisphosphonates before diagnosis was assessed in a subset of 933 pairs of postmenopausal female patients and controls, enrolled in Clalit Health Services, using computerized pharmacy records. RESULTS: The use of bisphosphonates for more than 1 year before diagnosis, but not for less than 1 year, was associated with a significantly reduced relative risk (RR) of colorectal cancer (RR, 0.50; 95% CI, 0.35 to 0.71). This association remained statistically significant after adjustment in a model for vegetable consumption, sports activity, family history of colorectal cancer, body mass index, and use of low-dose aspirin, statins, vitamin D, and postmenopausal hormones (RR, 0.41; 95% CI, 0.25 to 0.67). Concomitant use of bisphosphonates and statins did not further reduce the risk. CONCLUSION: The use of oral bisphosphonates for more than 1 year was associated with a 59% relative reduction in the risk of colorectal cancer, similar to the recently reported association of this drug class with reduction in breast cancer risk.
PURPOSE:Bisphosphonates are commonly used for the treatment of osteoporosis and bone metastases caused by breast cancer and were recently reported to be associated with a reduced risk of breast cancer, possibly acting through the mevalonate pathway, but their association with risk of other cancers is unknown. PATIENTS AND METHODS: The Molecular Epidemiology of Colorectal Cancer study is a population-based, case-control study in northern Israel of patients with colorectal cancer and age-, sex-, clinic-, and ethnic group-matched controls. Long-term use of bisphosphonates before diagnosis was assessed in a subset of 933 pairs of postmenopausal female patients and controls, enrolled in Clalit Health Services, using computerized pharmacy records. RESULTS: The use of bisphosphonates for more than 1 year before diagnosis, but not for less than 1 year, was associated with a significantly reduced relative risk (RR) of colorectal cancer (RR, 0.50; 95% CI, 0.35 to 0.71). This association remained statistically significant after adjustment in a model for vegetable consumption, sports activity, family history of colorectal cancer, body mass index, and use of low-dose aspirin, statins, vitamin D, and postmenopausal hormones (RR, 0.41; 95% CI, 0.25 to 0.67). Concomitant use of bisphosphonates and statins did not further reduce the risk. CONCLUSION: The use of oral bisphosphonates for more than 1 year was associated with a 59% relative reduction in the risk of colorectal cancer, similar to the recently reported association of this drug class with reduction in breast cancer risk.
Authors: Rowan T Chlebowski; Zhao Chen; Jane A Cauley; Garnet Anderson; Rebecca J Rodabough; Anne McTiernan; Dorothy S Lane; Joann E Manson; Linda Snetselaar; Shagufta Yasmeen; Mary Jo O'Sullivan; Monika Safford; Susan L Hendrix; Robert B Wallace Journal: J Clin Oncol Date: 2010-06-21 Impact factor: 44.544
Authors: Margaret A Gates; Shelley S Tworoger; A Heather Eliassen; Stacey A Missmer; Susan E Hankinson Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-03-23 Impact factor: 4.254
Authors: Tilman D Rachner; Shiv K Singh; Michael Schoppet; Peggy Benad; Martin Bornhäuser; Volker Ellenrieder; Regina Ebert; Franz Jakob; Lorenz C Hofbauer Journal: Cancer Lett Date: 2009-07-03 Impact factor: 8.679
Authors: Chris R Cardwell; Christian C Abnet; Philip Veal; Carmel M Hughes; Marie M Cantwell; Liam J Murray Journal: Int J Cancer Date: 2012-01-11 Impact factor: 7.396
Authors: Venkateshwar Madka; Gaurav Kumar; Gopal Pathuri; Yuting Zhang; Stanley Lightfoot; Adam S Asch; Altaf Mohammed; Vernon E Steele; Chinthalapally V Rao Journal: Cancer Prev Res (Phila) Date: 2019-11-07